FNY Managed Accounts LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.

Quarter-by-quarter ownership
FNY Managed Accounts LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2017$417,000
+6850.0%
7,200
+11900.0%
0.54%
+2768.4%
Q1 2017$6,00060
-25.0%
0.02%
Q3 2016$0
-100.0%
80
+66.7%
0.00%
-100.0%
Q1 2016$46,100,000
+62.1%
48
-73.0%
0.08%
-42.6%
Q4 2015$28,438,000
-91.7%
178
-92.9%
0.14%
-85.2%
Q3 2015$341,416,0002,5110.96%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders